<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860857</url>
  </required_header>
  <id_info>
    <org_study_id>2017-3832</org_study_id>
    <secondary_id>R01AG053555-02</secondary_id>
    <nct_id>NCT03860857</nct_id>
  </id_info>
  <brief_title>MRI and PET Biomarkers for Cognitive Decline in Older Adults</brief_title>
  <official_title>MRI and PET Biomarkers for Cognitive Decline in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to understand the factors that underlie changes in
      thinking and memory with increasing age. The investigators will test the usefulness of MRI,
      PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive
      decline. An addendum to this study includes additional PET scans to examine the relationship
      between tau protein in the brain and cognitive decline. Tau is a protein that is known to
      form tangles in the areas of the brain important for memory, and these tau tangles are a
      hallmark of Alzheimer's disease. This sub-study research aims to look at the tau accumulation
      in the brain using an investigational drug called MK-6240, which is a radio tracer that gets
      injected prior to a positron emission tomography (PET) scan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigates the relationship between Alzheimer's disease (AD) pathology, brain
      structure and function, as well as cognition in non-demented older adults. The goal is to
      develop a more complete understanding of the factors that lead to cognitive decline in the
      elderly and progression to AD. The investigators will enroll 200 cognitively intact adults
      between the ages of 60-85 years old from the UCI Alzheimer's Disease Research Center or
      directly from the local community. Study procedures will include: 1) PET amyloid scans with
      Amyvidâ„¢ radiotracer (florbetapir-F18) and PET tau scans with [18F]MK6240 radiotracer; 2)
      High-resolution structural, functional, and diffusion MRI; and 3) Cognitive examinations. The
      investigators will track cognitive outcomes through longitudinal monitoring. Amyloid imaging
      will only be conducted once in the study at baseline, and MRI and tau PET imaging will be at
      baseline and Year 1. The investigators aim to identify the best combination of tests for
      predicting longitudinal cognitive/clinical decline. The proposed study will significantly
      inform the understanding of cognitive decline in the aging brain and allow investigators to
      better define preclinical AD and make recommendations for future intervention trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 22, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants will complete the same study procedures, including the tau PET scans with investigational radio tracer 18F-MK6240. The arms define the age range and APOE status of the participants, with each having their own enrollment target.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clinical Dementia Rating - Sum of Box Score</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>A measure of cognitive/clinical decline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lure discrimination index - objects</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of performance on the object pattern separation task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lure discrimination index - spatial</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of performance on the spatial pattern separation task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lure discrimination index - temporal</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of performance on the temporal pattern separation task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in entorhinal cortical thickness</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of structural decline on MRI scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perforant path integrity</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of structural connectivity decline on MRI scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tau spatial distribution - advancing Braak stage</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of tau spatial spread on tau PET scans</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>Age 60-65 ApoE e4+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 60-65 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 66-70 ApoE e4-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 66-70 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 66-70 ApoE e4+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 66-70 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 71-75 ApoE e4-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 71-75 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 71-75 ApoE e4+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 71-75 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 76-80 ApoE e4-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 76-80 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 76-80 ApoE e4+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 76-80 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 81-85 ApoE e4-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 81-85 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 81-85 ApoE e4+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 81-85 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Amyloid PET scan</intervention_name>
    <description>Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18</description>
    <arm_group_label>Age 60-65 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4-</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4+</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4-</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4+</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4-</arm_group_label>
    <arm_group_label>Age 81-85 ApoE e4+</arm_group_label>
    <arm_group_label>Age 81-85 ApoE e4-</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tau PET scan using MK-6240</intervention_name>
    <description>Tau Positron Emission Tomography scan using radio tracer MK-6240</description>
    <arm_group_label>Age 60-65 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4-</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4+</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4-</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4+</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4-</arm_group_label>
    <arm_group_label>Age 81-85 ApoE e4+</arm_group_label>
    <arm_group_label>Age 81-85 ApoE e4-</arm_group_label>
    <other_name>tau PET</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Neurocognitive testing</intervention_name>
    <description>A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.</description>
    <arm_group_label>Age 60-65 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4-</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4+</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4-</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4+</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4-</arm_group_label>
    <arm_group_label>Age 81-85 ApoE e4+</arm_group_label>
    <arm_group_label>Age 81-85 ApoE e4-</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.</description>
    <arm_group_label>Age 60-65 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4-</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4+</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4-</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4+</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4-</arm_group_label>
    <arm_group_label>Age 81-85 ApoE e4+</arm_group_label>
    <arm_group_label>Age 81-85 ApoE e4-</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between the ages of 60 and 85;

          2. Speaks fluent English;

          3. Visual and auditory acuity adequate for neuropsychological and computerized testing;

          4. Good general health with no disease(s) expected to interfere with the study;

          5. Willing and able to participate for the duration of the study and in all study
             procedures including MRI and PET;

          6. Normal cognition defined as a Clinical Dementia Rating of 0 and a Mini-Mental State
             Examination score of 27 or higher.

        Exclusion Criteria:

          1. Significant co-morbid neurologic disease such as Parkinson's disease, multiple
             sclerosis, brain cyst, tumor or aneurysm;

          2. Major health conditions such as uncontrolled diabetes mellitus, uncontrolled
             hypertension, nutritional deficiency or uncontrolled thyroid disease;

          3. Significant psychiatric disorders such as schizophrenia, bipolar disorder, anxiety
             disorder, major depressive disorder, or attention-deficit hyperactivity disorder;

          4. ADRC consensus diagnosis of dementia or mild cognitive impairment;

          5. Cognitive impairment when tested at baseline (defined as a score on any
             neuropsychological test of 1.5 SDs or more outside the age norm);

          6. Alcohol or substance abuse or dependence within the past 2 years (DSM-IV criteria);

          7. MRI contraindications, e.g. pacemakers, aneurysm clips, artificial heart valves, ear
             implants, metal fragments or foreign objects in the eyes, skin or body. Females who
             are pregnant or trying to get pregnant are also excluded;

          8. PET contraindications, e.g. significant prior radiation exposure and pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Yassa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liv C McMillan, BS, CCRP</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myra S Larson, BA</last_name>
    <phone>949-824-0314</phone>
    <email>mslarson@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Blake A Miranda, BS</last_name>
    <phone>949-824-4094</phone>
    <email>bamirand@uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myra S Larson, BA</last_name>
      <phone>949-824-0314</phone>
      <email>mslarson@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Blake A Miranda, BS</last_name>
      <phone>949-824-4094</phone>
      <email>bamirand@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael A Yassa, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://faculty.sites.uci.edu/myassa/get-involved/participate-in-studies/</url>
    <description>Yassa Lab website</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>March 7, 2019</last_update_submitted>
  <last_update_submitted_qc>March 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Michael Yassa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer disease</keyword>
  <keyword>cognitive impairment</keyword>
  <keyword>mild cognitive impairment</keyword>
  <keyword>biomarker</keyword>
  <keyword>MRI</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

